Article info
PDFCommentary
Loss of KRAS control as consequence of downregulated microRNA-622 in hepatocellular carcinoma and its potential therapeutic implication
- Correspondence to Professor Ali Canbay, Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University, Magdeburg 39120, Germany; ali.canbay{at}med.ovgu.de
Citation
Loss of KRAS control as consequence of downregulated microRNA-622 in hepatocellular carcinoma and its potential therapeutic implication
Publication history
- Received January 3, 2018
- Revised January 4, 2018
- Accepted January 8, 2018
- First published January 20, 2018.
Online issue publication
June 26, 2018
Article Versions
- Previous version (26 June 2018).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.